IL-12
Information
- Drug Name
- IL-12
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| NK cells require DNAM-1 for natural or cytokine (I... | CD226 | CD226 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NK cell depletion significantly reduced both tumor... | TNFRSF9 | TNFRSF9 OVEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00004070 | Completed | Phase 1/Phase 2 | Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer | July 1999 | December 2000 |
| NCT00528489 | Completed | Phase 1 | Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults | October 2007 | January 2010 |
| NCT01266616 | Completed | Phase 1 | Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults | March 2011 | April 2013 |
| NCT02483312 | Recruiting | Phase 1 | A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) | September 2015 | August 2024 |
| NCT00057486 | Terminated | Phase 1/Phase 2 | Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients | September 1997 | June 2005 |